NCT01000688 is a Phase 3 clinical trial of vildagliptin + acarbose in Type 2 Diabetes, sponsored by Radboud University Medical Center.

Who is sponsoring NCT01000688?

NCT01000688 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT01000688?

Interventions in NCT01000688: vildagliptin + acarbose, acarbose + vildagliptin.

What condition does NCT01000688 study?

NCT01000688 studies Type 2 Diabetes, Endothelial Dysfunction.

Is NCT01000688 still recruiting?

NCT01000688 is currently completed. Last updated 4 November 2010.

Last reviewed 2010-11-04 · How we verify

NCT01000688

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Vildagliptin on Endothelium-dependent Vasodilatation. A Double Blind Cross-over Study in Type 2 Diabetes Mellitus.

Completed Phase 3 Last updated 4 November 2010

What this trial tests

Phase 3 trial testing vildagliptin + acarbose in Type 2 Diabetes in 16 participants. Completed in 1 October 2010.

Timeline

1 January 2010

Primary endpoint
1 August 2010

1 October 2010

Quick facts

Lead sponsor	Radboud University Medical Center
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	prevention
Enrollment	16
Start date	1 January 2010
Primary completion	1 August 2010
Estimated completion	1 October 2010
Sites	1 location across Netherlands

Drugs / interventions tested

vildagliptin + acarbose — full drug profile →
acarbose + vildagliptin — full drug profile →

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →
Endothelial Dysfunction — all drugs for Endothelial Dysfunction →

Sponsor

Radboud University Medical Center

Who can join

Adults 35 to 75, any sex, with Type 2 Diabetes or Endothelial Dysfunction. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Forearm vasodilator response to intra-arterial infusion of acetylcholine (endothelium-dependent) following treatment with vildagliptin and following active control with acarbose
Time frame: 8 weeks

Sponsor's own description

Rationale: Cardiovascular complications in type 2 diabetes are the leading cause of morbidity and mortality associated with the disease. Endothelial dysfunction is regarded as an important factor in these vascular complications. The introduction of glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes is of special interest because of possible influences on endothelial function. Numerous reports have shown that GLP-1 improves endothelial function. Objective: To determine whether a four week treatment with vildagliptin compared to acarbose improves endothelial dysfunction in patients with type 2 diabetes mellitus.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes.
van Poppel PC, Netea MG, Smits P, Tack CJ. · · 2011 · cited 92× · PMID 21788633 · DOI 10.2337/dc10-2421

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01000688 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 4 November 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01000688.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing